Details for New Drug Application (NDA): 205239
✉ Email this page to a colleague
NDA 205239 describes DANTROLENE SODIUM, which is a drug marketed by Elite Labs Inc, Impax Labs, Eugia Pharma Speclts, and Hikma, and is included in four NDAs. It is available from eight suppliers. Additional details are available on the DANTROLENE SODIUM profile page.
The generic ingredient in DANTROLENE SODIUM is dantrolene sodium. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
The generic ingredient in DANTROLENE SODIUM is dantrolene sodium. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
Summary for 205239
| Tradename: | DANTROLENE SODIUM |
| Applicant: | Eugia Pharma Speclts |
| Ingredient: | dantrolene sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 205239
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/VIAL | ||||
| Approval Date: | Feb 18, 2016 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
